University of Michigan Background
Thrombosis is a medical condition in which blood clots form within blood vessels and obstruct blood flow throughout the body. Thrombosis affects 1-2 people per 1,000 and remains a leading cause of disability. Polyphosphate (polyP) is secreted by activated platelets and has been shown to contribute to thrombosis. PolyP has remained an elusive target for antithrombotic therapy due to toxicity of polyP inhibitors.
This technology consists of a novel class of nontoxic polycationic polyP inhibitors. These compounds have been tested both in vitro and in vivo and have shown strong procoagulant activity with no evidence of increased risk of bleeding.
This technology consists of a novel class of nontoxic polyP inhibitors. Such inhibitors have not previously been produced due to toxic effects. These inhibitors have been successfully tested both in vitro and in vivo and have shown no signs of toxicity, making them a viable treatment option for thrombosis.
Potential anticoagulant preventative therapy such as during and after surgery